Triple-Negative Breast Cancer: One Or More Entities?

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.10.3322/caac.2013822237781Search in Google Scholar

[2] Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.10.1200/JCO.2009.25.6529288185520404251Search in Google Scholar

[3] Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.10.1200/JCO.2013.50.998424101045Search in Google Scholar

[4] Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60.10.1200/JCO.2005.03.384516145060Search in Google Scholar

[5] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.10.1056/NEJMra100138921067385Search in Google Scholar

[6] Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23 Suppl 6:vi7-12.10.1093/annonc/mds18723012306Search in Google Scholar

[7] Trivers KF, Lund MJ, Porter PL et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-82.10.1007/s10552-009-9331-1485268619343511Search in Google Scholar

[8] Kwan ML, Kushi LH, Weltzien E et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009;11:R31.10.1186/bcr2261271649919463150Search in Google Scholar

[9] Stead LA, Lash TL, Sobieraj JE et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11:R18.10.1186/bcr2242268894619320967Search in Google Scholar

[10] Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.10.1001/jama.295.21.249216757721Search in Google Scholar

[11] Huo D, Ikpatt F, Khramtsov A et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009 Sep;27:4515-21.10.1200/JCO.2008.19.6873275490419704069Search in Google Scholar

[12] Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.10.1007/s10549-007-9632-6244310317578664Search in Google Scholar

[13] Phipps AI, Chlebowski RT, Prentice R et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011;103:470−477.10.1093/jnci/djr030305798421346227Search in Google Scholar

[14] Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under age 45. Cancer Epidemiol Biomarkers Prev 2009;18:1157−1166.10.1158/1055-9965.EPI-08-1005275471019336554Search in Google Scholar

[15] Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:307-14.10.1007/s10549-012-2339-323179600Search in Google Scholar

[16] Chen WY, Rosner B, Hankinson SE et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011;306:1884-90.10.1001/jama.2011.1590329234722045766Search in Google Scholar

[17] Liu Y, Colditz GA, Rosner B et al. Alcohol intake between menarche and frst pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst 2013;105:1571-8.10.1093/jnci/djt213379702323985142Search in Google Scholar

[18] Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat 2006;100:293-9.10.1007/s10549-006-9255-316773435Search in Google Scholar

[19] Johnson KC, Miller AB, Collishaw NE et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control 2011;20:e2.10.1136/tc.2010.03593121148114Search in Google Scholar

[20] Kabat GC, Kim M, Phipps AI et al. Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control 2011;22:775−783.10.1007/s10552-011-9750-7310034721360045Search in Google Scholar

[21] Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.10.1038/modpathol.380052816341146Search in Google Scholar

[22] Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013;19:6380-8.10.1158/1078-0432.CCR-13-091524298068Search in Google Scholar

[23] Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.10.1158/1078-0432.CCR-06-304517671126Search in Google Scholar

[24] Collett K, Stefansson IM, Eide J et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14:1108-12.10.1158/1055-9965.EPI-04-039415894660Search in Google Scholar

[25] Edge SB, Byrd DR, Compton CC et al (Eds). AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Springer-Verlag, New York 2010. p.347Search in Google Scholar

[26] Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.10.1200/JCO.2007.14.414718250347Search in Google Scholar

[27] Dent R, Hanna WM, Trudeau M et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-8.10.1007/s10549-008-0086-218543098Search in Google Scholar

[28] Lin NU, Vanderplas A, Hughes ME et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118:5463-72.10.1002/cncr.27581361165922544643Search in Google Scholar

[29] Hamm C, El-Masri M, Poliquin G et al. A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 2011;18:191-6.10.3747/co.v18i4.815314954721874118Search in Google Scholar

[30] Iwase H, Kurebayashi J, Tsuda H et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 2010;17:118-24.10.1007/s12282-009-0113-019466512Search in Google Scholar

[31] Perou CM, S⊘rlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.10.1038/3502109310963602Search in Google Scholar

[32] Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23.10.1093/annonc/mdt303375533423917950Search in Google Scholar

[33] Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.10.1158/1078-0432.CCR-04-022015328174Search in Google Scholar

[34] Prat A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013;18:123-33.10.1634/theoncologist.2012-0397357959523404817Search in Google Scholar

[35] Turner N, Lambros MB, Horlings HM et al. Integrative molecular profling of triple negative breast cancers identifes amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013-23.10.1038/onc.2009.489285251820101236Search in Google Scholar

[36] Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.10.1200/JCO.2007.13.174818487574Search in Google Scholar

[37] Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.10.1038/nature10933386368122495314Search in Google Scholar

[38] Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.10.1186/bcr2635309695420813035Search in Google Scholar

[39] Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.10.1056/NEJMra080128919228622Search in Google Scholar

[40] Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750−67.10.1172/JCI45014312743521633166Search in Google Scholar

[41] Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160-7.10.1200/JCO.2008.18.1370266782019204204Search in Google Scholar

[42] Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014;232:142-50.10.1002/path.4280409003124114677Search in Google Scholar

[43] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61−70.10.1038/nature11412346553223000897Search in Google Scholar

[44] Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008;10:R101.10.1186/bcr2204265689719055754Search in Google Scholar

[45] López-Knowles E, O'Toole SA, McNeil CM et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.10.1002/ijc.2483119685490Search in Google Scholar

[46] Jiang Z, Jones R, Liu JC et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011;10:1563-70.10.4161/cc.10.10.1570321502814Search in Google Scholar

[47] Hu X, Stern HM, Ge L et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009;7:511-22.10.1158/1541-7786.MCR-08-010719372580Search in Google Scholar

[48] Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9.10.1158/1078-0432.CCR-10-2560304892421233401Search in Google Scholar

[49] Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basallike breast cancer. Oncogene 2007;26:2126-32.10.1038/sj.onc.121001417016441Search in Google Scholar

[50] Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004;4:814-9.10.1038/nrc145715510162Search in Google Scholar

[51] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2014. http://www.nccn. org/professionals/physician_gls/pdf/breast.pdf (Accessed on May 4, 2014)Search in Google Scholar

[52] Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67.10.1001/jama.295.14.1658145954016609087Search in Google Scholar

[53] Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007;357:1496-506.10.1056/NEJMoa071167Search in Google Scholar

[54] Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92.10.1016/S0140-6736(09)60740-6Search in Google Scholar

[55] Martín M, Rodríguez-Lescure A, Ruiz A et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010;123:149-57.10.1007/s10549-009-0663-zSearch in Google Scholar

[56] Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.10.1158/1078-0432.CCR-06-1109Search in Google Scholar

[57] Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-40.10.1007/s10549-010-1103-9Search in Google Scholar

[58] Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.10.1200/JCO.2005.02.6914Search in Google Scholar

[59] von Minckwitz G, Untch M, Blohmer JU et al. Defnition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.10.1200/JCO.2011.38.8595Search in Google Scholar

[60] Masuda H, Baggerly KA, Wang Y et al. Differential response to neoadjuvant chemotherapy among seven triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533 − 5540.10.1158/1078-0432.CCR-13-0799Search in Google Scholar

[61] Chen X, Li J, Gray WH et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform 2012;11:147−56.10.4137/CIN.S9983Search in Google Scholar

[62] Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339− 49.10.1016/S1470-2045(10)70008-5Search in Google Scholar

[63] Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999−1005.Search in Google Scholar

[64] Nik-Zainal S, Van Loo P, Wedge DC et al. The life history of 21 breast cancers. Cell 2012;149: 994− 1007.10.1016/j.cell.2012.04.023Search in Google Scholar

[65] Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.10.1200/JCO.2009.22.4725Search in Google Scholar

[66] Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-52.10.1093/annonc/mdn395Search in Google Scholar

[67] von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; Published Online May 1.10.1016/S1470-2045(14)70160-3Search in Google Scholar

[68] Bhattacharyya GS, Basu S, Agarwal V et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer 2009;7:18:Abstr 41LBA10.1016/S1359-6349(09)72076-2Search in Google Scholar

[69] Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52:25-33.10.1016/j.phrs.2005.02.010Search in Google Scholar

[70] Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.10.1016/S0140-6736(10)60892-6Search in Google Scholar

[71] Isakoff SJ, Overmoyer B, Tung NM, et al A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010;28(15s):abstr 1019.10.1200/jco.2010.28.15_suppl.1019Search in Google Scholar

[72] O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29(81s):abstr 100710.1200/jco.2011.29.15_suppl.1007Search in Google Scholar

[73] Gelmon K, Dent R, Mackey JR et al. Targeting triple-negative breast cancer: optimizing therapeutic outcomes. Ann Oncol 2012;23:2223-34.10.1093/annonc/mds06722517820Search in Google Scholar

[74] Barbieri CE, Pietenpol JA. p63 and epithelial biology. Exp Cell Res 2006;312:695−706.10.1016/j.yexcr.2005.11.02816406339Search in Google Scholar

[75] Rosenbluth JM, Mays DJ, Jiang A et al. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci USA 2011;108:2076−81.10.1073/pnas.1011936108303330621245298Search in Google Scholar

[76] Mayer IA, Jovanovic B, Abramson VG et al. A Triple-negative breast cancer: one or more entities? randomized phase II neoadjuvant study of cisplatin, pac- litaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2013; Poster Discussion PD1-6.10.1158/0008-5472.SABCS13-PD1-6Search in Google Scholar

[77] Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472-8.10.1158/1078-0432.CCR-08-176319276248Search in Google Scholar

[78] Ibrahim YH, Garcia-Garcia C, Serra V et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-profcient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2:1036-47.10.1158/2159-8290.CD-11-0348512525422915752Search in Google Scholar

[79] Hoefich KP, O'Brien C, Boyd Z et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-64.10.1158/1078-0432.CCR-09-031719567590Search in Google Scholar

[80] Balko JM, Cook RS, Vaught DB et al. Profling of residual breast cancers after neoadjuvant chemotherapy identifes DUSP4 defciency as a mechanism of drug resistance. Nat Med 2012;18:1052-9.10.1038/nm.2795369356922683778Search in Google Scholar

[81] Linderholm BK, Hellborg H, Johansson U et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009;20:1639-1646.10.1093/annonc/mdp06219549711Search in Google Scholar

[82] von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.10.1056/NEJMoa111106522276820Search in Google Scholar

[83] Bear HD, Tang G, Rastogi P et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29:Abstr LBA 1005.10.1200/jco.2011.29.15_suppl.lba1005Search in Google Scholar

[84] O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 2009;69:Abstr 207.10.1158/0008-5472.SABCS-09-207Search in Google Scholar

[85] O'Shaughnessy J, Romieu G, Dieras V et al. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of frst-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010;70:Abstr P6-12-03.10.1158/0008-5472.SABCS10-P6-12-03Search in Google Scholar

[86] Brufsky A, Valero V, Tiangco B et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. J Clin Oncol 2011;29:Abstr 1010.10.1200/jco.2011.29.15_suppl.1010Search in Google Scholar

[87] Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810−181610.1200/JCO.2007.14.537518347007Search in Google Scholar

[88] Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11−15.10.1200/JCO.2007.15.5242264509419047293Search in Google Scholar

[89] Crown J, Dieras V, Staroslawska E et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol. 2013;31:2870-8.10.1200/JCO.2012.43.339123857972Search in Google Scholar

[90] Baselga J, Roche H, Costa F et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009;69:Abstr 4510.1158/0008-5472.SABCS-09-45Search in Google Scholar

[91] Baselga J, Stemmer S, Pego A et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triplenegative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010;70:Abstr PD01−01.10.1158/0008-5472.SABCS10-PD01-01Search in Google Scholar

[92] O'Shaughnessy J, Weckstein D, Vukelja S et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007;106:S32:Abstr 308.Search in Google Scholar

[93] Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008;26:Abstr 1009.10.1200/jco.2008.26.15_suppl.1009Search in Google Scholar

[94] Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as frst-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009;27:3908−3915.10.1200/JCO.2008.18.1925279915119620495Search in Google Scholar

[95] Sharma P, Khan QJ, Kimler BF et al. Results of a phase II study of neoadjuvant platinum/taxane based chemotherapy and erlotinib for triple negative breast cancer. Cancer Res 2010;70:Abstr P1-11-07.10.1158/0008-5472.SABCS10-P1-11-07Search in Google Scholar

[96] Finn R, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res 2009; 69:Abstr 3118.10.1158/0008-5472.SABCS-3118Search in Google Scholar

[97] Gonzalez-Angulo AM, Green MC, Murray JL et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). J Clin Oncol 2011;29:Abstr 1016.10.1200/jco.2011.29.15_suppl.1016Search in Google Scholar

[98] Singh JC, Novik Y, Stein S et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014;16:R32.10.1186/bcr3634405357524684785Search in Google Scholar

[99] Gucalp A, Tolaney SM, Isakoff SJ et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). J Clin Oncol 2012;30 suppl:abstr 1006.10.1200/jco.2012.30.15_suppl.1006Search in Google Scholar